Crigler-Najjar syndrome is a rare genetic condition where the liver cannot properly break down a substance called bilirubin, leading to its dangerous buildup in the body. This disorder causes persistent yellowing of the skin and eyes, and without proper treatment, can lead to severe brain damage, particularly in infants and young children.

Epidemiology

Crigler-Najjar syndrome is exceptionally rare throughout the world. Current estimates suggest that the condition affects fewer than 1 in 1 million newborns globally.^[1] Some studies have placed the incidence slightly higher, between 0.6 and 1 in 1 million live births.^[2] This makes Crigler-Najjar syndrome one of the rarest inherited liver disorders affecting children.

The condition does not appear to show a strong preference for any particular sex or ethnic group, affecting males and females in roughly equal numbers.^[18] However, certain populations may see slightly higher rates due to genetic factors. The syndrome can affect anyone regardless of their background, though families with a history of the condition or those from communities where marriages between relatives are more common may have a somewhat elevated risk of passing the disorder to their children.

Because Crigler-Najjar syndrome is so uncommon, only around 100 cases have been recorded in medical literature.^[17] This rarity can make diagnosis challenging, as many healthcare providers may never encounter a case during their entire careers. The condition typically becomes apparent within the first days or weeks after birth, though the severity of symptoms can vary significantly depending on which type of the syndrome a child has inherited.

Causes

Crigler-Najjar syndrome is caused by mutations in a specific gene called UGT1A1. This gene provides the instructions that tell the body how to make an enzyme with a long name: bilirubin uridine diphosphate glucuronosyltransferase, often shortened to bilirubin-UGT or simply UGT.^[3] This enzyme plays a critical role in helping the liver process bilirubin, a yellowish-orange substance that naturally forms when red blood cells break down at the end of their lifespan.

When the UGT1A1 gene carries certain mutations, the enzyme it produces either doesn’t work properly or isn’t made at all. The enzyme’s job is to perform a chemical reaction called glucuronidation. During this process, the enzyme attaches a compound called glucuronic acid to bilirubin molecules. This attachment changes bilirubin from a toxic form that cannot dissolve in water (called unconjugated bilirubin) into a safer form that can dissolve in water (called conjugated bilirubin).^[3] Once bilirubin is converted to its water-soluble form, the body can eliminate it through bile and eventually through stool.

Without functional UGT enzyme activity, unconjugated bilirubin accumulates in the bloodstream and tissues throughout the body. This toxic buildup is what causes the symptoms and complications of Crigler-Najjar syndrome. The severity of the condition depends on how much enzyme activity remains. In Type 1, the most severe form, there is essentially no enzyme function at all. In Type 2, there is reduced enzyme activity—typically less than 20 percent of normal levels—but some function does remain.^[2]

Crigler-Najjar syndrome follows an autosomal recessive pattern of inheritance.^[3] This means that a child must receive a mutated copy of the UGT1A1 gene from both parents to develop the full syndrome. Parents who carry only one mutated gene copy are called carriers. Carriers typically have about half the normal enzyme activity but do not show symptoms of the disease. When both parents are carriers, each pregnancy has a 25 percent chance of producing a child with Crigler-Najjar syndrome, a 50 percent chance of producing a carrier child, and a 25 percent chance of producing a child with two normal gene copies.

Risk Factors

The primary risk factor for Crigler-Najjar syndrome is having parents who both carry mutations in the UGT1A1 gene. Because the condition follows an autosomal recessive inheritance pattern, children are only at risk when both parents pass along a defective gene copy. Families with a known history of Crigler-Najjar syndrome in previous generations should be aware that the genetic mutations may be present and could be passed to future children.

Communities where marriages between relatives are more common may see higher rates of Crigler-Najjar syndrome and other recessive genetic disorders. This is because related individuals are more likely to carry the same genetic mutations. When two relatives who are both carriers have children together, the risk that their children will inherit two mutated gene copies increases significantly compared to the general population.

For individuals who already have Crigler-Najjar syndrome, certain situations can temporarily worsen their condition or trigger complications. In Type 2 Crigler-Najjar syndrome, periods of physical or emotional stress can cause bilirubin levels to rise and jaundice to become more pronounced.^[2] Infections, illnesses, trauma, or surgery can also cause sudden spikes in bilirubin levels. In patients with Type 2, events such as severe infections or injuries could potentially trigger enough bilirubin buildup to cause brain damage, even though their baseline levels are usually safer than those with Type 1.

Certain medications and substances can interfere with bilirubin processing or compete with the limited enzyme function present in Type 2 patients. Healthcare providers managing patients with Crigler-Najjar syndrome must carefully consider drug interactions and avoid medications that could worsen bilirubin accumulation. Fasting or prolonged periods without eating can also cause bilirubin levels to rise temporarily.

Symptoms

The hallmark symptom of Crigler-Najjar syndrome is jaundice, which refers to the yellowish discoloration of the skin and the whites of the eyes. This yellowing appears because of high levels of bilirubin circulating in the blood and depositing in tissues. In newborns with Crigler-Najjar syndrome, jaundice typically appears within the first few days after birth.^[1] While mild jaundice is common in many healthy newborns and usually resolves within the first week of life, babies with Crigler-Najjar syndrome have jaundice that persists well beyond the typical newborn period and often becomes more intense over time.

The severity and range of symptoms depend heavily on which type of Crigler-Najjar syndrome a person has. In Type 1, the most severe form, bilirubin levels typically rise above 20 milligrams per deciliter and can reach extremely dangerous levels exceeding 44 milligrams per deciliter.^[5] These extremely high bilirubin concentrations put infants at immediate risk for serious complications. In Type 2, bilirubin levels are lower, usually ranging between 3.5 and 20 milligrams per deciliter, which still causes noticeable jaundice but with less immediate danger of brain damage.

Beyond jaundice, infants and children with untreated or inadequately treated Crigler-Najjar syndrome may experience additional symptoms. These can include poor feeding, extreme tiredness or sluggishness, irritability, and episodes of vomiting.^[18] Some children develop digestive symptoms such as stomach pain or diarrhea. As bilirubin levels climb higher, more concerning neurological symptoms may appear, including confusion, slurred speech, difficulty swallowing, changes in walking patterns with frequent stumbling or staggering, and in severe cases, seizures.^[5]

Kernicterus and Brain Damage

The most serious complication of Crigler-Najjar syndrome is a condition called kernicterus, also known as bilirubin encephalopathy. This occurs when extremely high levels of unconjugated bilirubin cross into the brain and nervous system, where the substance becomes toxic to nerve cells and causes permanent damage.^[1] Kernicterus is a life-threatening emergency and can result in severe, irreversible neurological problems or death if not treated urgently.

In infants with Type 1 Crigler-Najjar syndrome, symptoms of kernicterus typically begin to appear after the first month of life or during early childhood, though they can develop earlier if bilirubin levels are extremely elevated. Early warning signs of kernicterus include a baby becoming extremely tired and difficult to wake, developing very weak and floppy muscles (described as being like a rag doll), producing a high-pitched cry, losing the normal startle reflex, and showing poor feeding behavior.^[18] As the condition progresses, affected children may develop rigid muscle tone, arching of the back, and episodes of fever.

Children who survive the acute phase of kernicterus often develop permanent disabilities. Mild to moderate symptoms can include clumsiness, muscle spasms, problems with sensory perception (such as difficulty processing what they see, hear, or feel), and trouble with fine motor skills like grasping small objects or fastening buttons.^[1] Many affected individuals develop a movement disorder called choreoathetosis, which causes involuntary twisting, writhing, or squirming movements of the body. Dental problems are also common, with many children showing underdeveloped enamel on their teeth.

More severe cases of kernicterus can lead to profound hearing loss or complete deafness, intellectual disability, paralysis of eye movements, significant mental impairment, and developmental delays.^[12] These complications underscore why early diagnosis and consistent treatment are absolutely critical for children with Crigler-Najjar syndrome, particularly Type 1.

Prevention

Because Crigler-Najjar syndrome is an inherited genetic condition, it cannot be prevented in the traditional sense. However, families with a known history of the syndrome or those who have already had one affected child can take steps to understand their risks and make informed decisions about future pregnancies. Genetic counseling is strongly recommended for anyone with a personal or family history of Crigler-Najjar syndrome who is planning to have children.^[1]

Genetic counselors can help prospective parents understand how the condition is inherited and what the chances are of passing it to their children. Blood tests can identify whether individuals carry mutations in the UGT1A1 gene.^[3] If both parents are confirmed carriers, they can be informed that each pregnancy carries a 25 percent risk of producing a child with Crigler-Najjar syndrome. This information allows families to make educated choices about family planning and to prepare for the possibility of having an affected child.

For pregnancies where both parents are known carriers, prenatal testing options are available. Procedures such as chorionic villus sampling or amniocentesis can analyze the developing baby’s DNA to determine whether the child has inherited two mutated gene copies and will therefore have Crigler-Najjar syndrome. These tests carry some risks and should be discussed thoroughly with healthcare providers and genetic counselors.

For individuals already diagnosed with Crigler-Najjar syndrome, preventing complications rather than preventing the disease itself becomes the focus. Consistent adherence to treatment plans is essential. For children with Type 1 who require daily phototherapy, maintaining the recommended schedule of light treatment is critical to preventing dangerous bilirubin spikes. Avoiding situations that can trigger bilirubin increases—such as certain medications, prolonged fasting, or untreated infections—is also important.

Regular monitoring of bilirubin levels through blood tests allows healthcare teams to detect rising levels early and adjust treatment accordingly. Families should work closely with liver specialists and maintain frequent medical follow-up appointments. Quick action at the first signs of illness or stress can help prevent acute crises that might lead to kernicterus.

Pathophysiology

To understand how Crigler-Najjar syndrome affects the body, it helps to know how the liver normally processes bilirubin. Bilirubin is created when old red blood cells are broken down. Specifically, when the protein hemoglobin inside red blood cells is degraded, one of the byproducts is bilirubin. This newly formed bilirubin is in its unconjugated form—it cannot dissolve in water, is toxic to tissues (especially the brain), and cannot be eliminated from the body in its current state.

Unconjugated bilirubin travels through the bloodstream to the liver. In healthy individuals, liver cells take up this bilirubin and use the UGT enzyme to attach glucuronic acid molecules to it through the process of glucuronidation.^[2] This chemical modification transforms unconjugated bilirubin into conjugated bilirubin, which is water-soluble, non-toxic, and can be excreted. The conjugated bilirubin is released into bile, a digestive fluid produced by the liver. Bile flows into the intestines, where conjugated bilirubin is eventually eliminated from the body in stool, giving stool its characteristic brown color.

In people with Crigler-Najjar syndrome, mutations in the UGT1A1 gene result in either complete absence or severe reduction of functional UGT enzyme. Without adequate enzyme activity, the liver cannot efficiently convert unconjugated bilirubin to its conjugated form. As a result, unconjugated bilirubin accumulates in the bloodstream. This condition is called unconjugated hyperbilirubinemia—”hyper” meaning high, “bilirubinemia” meaning bilirubin in the blood, and “unconjugated” specifying that it is the toxic form.

The extent of enzyme dysfunction determines the severity of the syndrome. In Type 1 Crigler-Najjar syndrome, there is minimal to no UGT enzyme activity at all.^[2] Patients with Type 1 cannot perform glucuronidation effectively, leading to bilirubin levels that can exceed 20 milligrams per deciliter and sometimes reach life-threateningly high concentrations. Analysis of their bile shows it contains almost entirely unconjugated bilirubin with only trace amounts of the conjugated form.^[9] In Type 2, also called Arias syndrome, there is residual enzyme activity—usually less than 10 percent of normal function—which is enough to keep bilirubin levels somewhat lower and reduce the immediate risk of severe brain damage.

The accumulation of unconjugated bilirubin causes several physical changes in the body. Because bilirubin is an orange-yellow pigment, its buildup in the skin, mucous membranes, and the whites of the eyes produces the visible yellowing known as jaundice. More dangerously, unconjugated bilirubin can cross the blood-brain barrier, especially in infants whose brains are still developing and whose protective barriers are not yet fully mature. Once in the brain, bilirubin deposits in nerve tissues and structures called the basal ganglia, which control movement.

Bilirubin is toxic to neurons (nerve cells). At high concentrations, it disrupts the normal function and structure of brain cells, causing inflammation, cell death, and permanent scarring in brain tissue. This pathological process is what leads to kernicterus. The resulting brain damage manifests as the neurological symptoms described earlier: movement disorders, hearing loss, intellectual impairment, and various motor and sensory deficits. The degree of damage correlates with both the peak bilirubin concentration and the duration of exposure to high levels.

Because Type 1 patients lack the ability to conjugate bilirubin through their own liver function, treatments must either reduce bilirubin production, increase its elimination through alternative pathways, or provide a working liver through transplantation. Phototherapy uses special blue-spectrum light to convert unconjugated bilirubin in the skin into forms that can be excreted without needing liver processing. However, as children grow and their skin thickens, phototherapy becomes less effective because light cannot penetrate as deeply.

In Type 2 Crigler-Najjar syndrome, the small amount of residual enzyme activity makes a significant difference in the disease course. Although bilirubin levels are elevated, they typically remain below the threshold most likely to cause acute brain toxicity. Furthermore, certain medications such as phenobarbital can stimulate the expression of the UGT1A1 gene and boost the limited enzyme production.^[9] This allows some Type 2 patients to achieve better bilirubin control with medication alone, although they still require lifelong monitoring and treatment. Type 1 patients do not respond to phenobarbital because they have no functional enzyme to stimulate.